Q1 2022 Results

Company overview Financial review 2022 priorities Appendix References Top 2022 priorities for Novartis on track 1 Successful launches: Leqvio®, KesimptaⓇ, Pluvicto™, ScemblixⓇ 2 Maintain growth momentum: C E AZ KK L 3 Progress pipeline: 20+ assets with significant sales potential, approval by 2026, on track 4 Optimize portfolio: Sandoz review, update end 2022; disciplined business development 5 Deliver returns: Continue productivity initiatives. New organizational model announced 6 Reinforce foundations: Culture to drive performance, data science to drive value, ESG leadership 28 Investor Relations | Q1 2022 Results NOVARTIS | Reimagining Medicine

View entire presentation